» Articles » PMID: 32204562

Alarmins in Osteoporosis, RAGE, IL-1, and IL-33 Pathways: A Literature Review

Overview
Publisher MDPI
Specialty General Medicine
Date 2020 Mar 25
PMID 32204562
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Alarmins are endogenous mediators released by cells following insults or cell death to alert the host's innate immune system of a situation of danger or harm. Many of these, such as high-mobility group box-1 and 2 (HMGB1, HMGB2) and S100 (calgranulin proteins), act through RAGE (receptor for advanced glycation end products), whereas the IL-1 and IL-33 cytokines bind the IL-1 receptors type I and II, and the cellular receptor ST2, respectively. The alarmin family and their signal pathways share many similarities of cellular and tissue localization, functions, and involvement in various physiological processes and inflammatory diseases including osteoporosis. The aim of the review was to evaluate the role of alarmins in osteoporosis. A bibliographic search of the published scientific literature regarding the role of alarmins in osteoporosis was organized independently by two researchers in the following scientific databases: Pubmed, Scopus, and Web of Science. The keywords used were combined as follows: "alarmins and osteoporosis", "RAGE and osteoporosis", "HMGB1 and osteoporosis", "IL-1 and osteoporosis", "IL 33 and osteopororsis", "S100s protein and osteoporosis". The information was summarized and organized in the present review. We highlight the emerging roles of alarmins in various bone remodeling processes involved in the onset and development of osteoporosis, as well as their potential role as biomarkers of osteoporosis severity and progression. Findings of the research suggest a potential use of alarmins as pharmacological targets in future therapeutic strategies aimed at preventing bone loss and fragility fractures induced by aging and inflammatory diseases.

Citing Articles

Expression and significance of cytokines in peripheral blood and bone microenvironment in Kummell's disease, osteoporotic vertebral compression fractures and nonosteoporotic patients.

Li Z, Yao Q, Ning Y, Xu S, Yan J, Wang Q BMC Musculoskelet Disord. 2025; 26(1):232.

PMID: 40065254 PMC: 11892217. DOI: 10.1186/s12891-025-08472-8.


Mast Cells at the Crossroads of Hypersensitivity Reactions and Neurogenic Inflammation.

Aitella E, Romano C, Ginaldi L, Cozzolino D Int J Mol Sci. 2025; 26(3).

PMID: 39940696 PMC: 11817554. DOI: 10.3390/ijms26030927.


PRKD2 as a novel target for targeting the diabetes-osteoporosis nexus.

Chen R, Yang C, Xiao H, Yang A, Chen C, Yang F Sci Rep. 2025; 15(1):4703.

PMID: 39922871 PMC: 11807170. DOI: 10.1038/s41598-025-89235-2.


Olink and gut microbial metabolomics reveal new biomarkers for the prediction and diagnosis of PMOP.

Wu R, Wu J, Jin H, Ma H, Huang H, Xu W J Bone Miner Metab. 2024; 42(5):503-515.

PMID: 39153113 DOI: 10.1007/s00774-024-01545-z.


Structure and Functions of HMGB3 Protein.

Chikhirzhina E, Tsimokha A, Tomilin A, Polyanichko A Int J Mol Sci. 2024; 25(14).

PMID: 39062899 PMC: 11276821. DOI: 10.3390/ijms25147656.


References
1.
Kim J, Jin H, Kim K, Song I, Youn B, Matsuo K . The mechanism of osteoclast differentiation induced by IL-1. J Immunol. 2009; 183(3):1862-70. DOI: 10.4049/jimmunol.0803007. View

2.
Lloyd C . IL-33 family members and asthma - bridging innate and adaptive immune responses. Curr Opin Immunol. 2010; 22(6):800-6. PMC: 3380518. DOI: 10.1016/j.coi.2010.10.006. View

3.
Keller J, Catala-Lehnen P, Wintges K, Schulze J, Bickert T, Ito W . Transgenic over-expression of interleukin-33 in osteoblasts results in decreased osteoclastogenesis. Biochem Biophys Res Commun. 2011; 417(1):217-22. DOI: 10.1016/j.bbrc.2011.11.088. View

4.
Hanford L, Enghild J, Valnickova Z, Petersen S, Schaefer L, Schaefer T . Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem. 2004; 279(48):50019-24. PMC: 1868562. DOI: 10.1074/jbc.M409782200. View

5.
Franke S, Ruster C, Pester J, Hofmann G, Oelzner P, Wolf G . Advanced glycation end products affect growth and function of osteoblasts. Clin Exp Rheumatol. 2011; 29(4):650-60. View